Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Article
Sponsored Content
Dermavant Moves One Step Closer to Potential New Treatment Option for Patients with Plaque Psoriasis
Author(s):
Partner Perspectives
Click here for the NDA acceptance press release
Dermavant Sciences recently announced that the FDA accepted for filing a New Drug Application (NDA) for tapinarof for the treatment of plaque psoriasis in adult patients. Tapinarof is an investigational novel, therapeutic aryl hydrocarbon receptor modulating agent, in development as a once-daily, steroid-free and cosmetically elegant topical cream for the treatment of plaque psoriasis and atopic dermatitis. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date in Q2 2022.
Message from Dermavant CEO, Todd Zavodnick
Related Videos
Related Content
